

APRIL 2009 DUR BOARD MEETING MINUTES

Date: April 22, 2009

Members Present: Putsch, Brown, Burton, Sargent, Crichton, Bradley (via phone), Cobb (via phone)

Others Present: Roger Citron (Medicaid), Wendy Blackwood (Medicaid), Dan Petersen (Medicaid), Latisha Weeks (First Health), Marcella Barnhill (Drug PA/CM unit), Lisa Wilkinson (DUR Case Management) and various members of the public and representatives of drug manufacturers.

PDL Review:

The Board made the following recommendations to the Department:

The Department proposed no changes to **GROUP 1** and all available chemical entities are preferred :

- ALPHA-GLUCOSIDASE INHIBITORS
- MULTIPLE SCLEROSIS AGENTS
- SULFONYLUREAS-2ND GENERATION
- INCRETIN MIMETICS

The Board agreed with the Department's proposal

The Department proposed no changes to the Formulary Committee's clinical recommendations to **GROUP 2:**

- ALZHEIMER'S CHOLINESTERASE INHIBITORS
- ANTI-HYPER-LIPIDEMIC AGENTS
- ACE INHIBITORS & COMBOS
- NASAL CALCITONINS
- AIIRBs & COMBOS
- BISPHOSPHONATES
- BETA BLOCKERS & COMBOS
- BENZOYL PEROXIDE/CLINDAMYCIN COMBOS
- CALCIUM CHANNEL BLOCKERS

The Board agreed with the Department's proposal, but heard new evidence on the TZD & Combo class

The Department reviewed **GROUP 3** as **NEW** information is known to exist:

- INSULINS- APIDRA
- CARBAMAZEPINE DERIVATIVES
- MEGLITINIDES- PRANDIMET
- TZDs & Combos
- 1ST GENERATION ANTICONVULSANTS
- TRIGLYCERIDE LOWERING AGENTS- TRILIPIX
- 2ND GENERATION ANTICONVULSANTS
- NIACIN DERIVATIVES
- NON-ERGOT DOPAMINE RECEPTOR AGONISTS

The Board made the following decisions.

Anticonvulsants:

1st Generation:

Must have: Phenytoin, Mephobarbital, Primdone, Dilantin 30mg, Dilantin 50mg, Divalproex IR & ER, Ethosuximide Caps & Susp, Valproic Acid Caps & Susp

Do not add Felbatol (patients currently on Felbatol will be grandfathered), Dilantin Caps, Dilantin 125mg susp, Depakote IR,ER, and Sprinkles, Depakene Caps & Syrup, Stavzor, Zarontin, Mebaral, Mysoline

2nd Generation:

Must have:

Gabapentin, Lamotrigine, Levetiracetam, Lyrica, Topiramate, and Zonisamide, Lamictal Starter pack

May add:

Banzel, Gabitril

Do not add Keppra, Keppra XR, Neurontin Tablets, Capsules & Solution, Topamax Tablets & Sprinkles, Vimpat, Lamictal Tablets & Dispertabs

Carbamazepine Derivatives:

Must have:

Carbamazepine chewable, oral tablets and suspension, a long acting Carbamazepine (Carbatrol and/or Tegretol XR), and Oxcarbazepine

May add:

Carbatrol, Tegretol XR

Do not add Trileptal Tablets & Suspension, Equetro, Epitol, Tegretol Chewables, Tablets & Suspension

Thiazolidinediones & Combos:

Must have:

Actos, ActosplusMet

May add:

DuetAct

Do not add Avandia, Avandimet

Insulins:

No changes to previous decision

Meglitinides:

Must have:

Prandin

May add:

PrandiMet

Do not add Starlix

Triglyceride Lowering Agents:

Must have:

Gemfibrozil, a fenofibrate derivative (Antara, Fenoglide, Lipofen, Lofibra, Tricor or Triglide)

May add:

Trilipix, Lovaza

Niacin Derivatives:

Must have:

Niaspan

May add:

Niacor

Non-Ergot Dopamine Receptor Agonists:

Must have:

Mirapex and Ropinirole are class effect, must have one

Do not add Requip or Requip XL (requires trial on immediate release and diagnosis of Parkinsons)

The next PDL meeting will be held on May 27th at the Great Northern Hotel
Meeting was adjourned at 4:15